A Phase 3 interventional study of P-3073 and Vehicle of P-3073 in Nail Psoriasis, sponsored by Polichem S.A.. Completed at 7 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-03-08.
Sponsored by Polichem S.A. (part of Almirall, S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Psoriasis by Almirall, S.A. — 2 open to participants now, 3 under way, none of them phase 3. Psoriasis · Almirall, S.A..
Among the 20 studies in Psoriasis by Almirall, S.A., this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 3, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 20 studies in Psoriasis by Almirall, S.A. are open now, in 1 country. Recruiting first, the newest first:
Almirall, S.A. · Sites in Austria
Ages 18–99
Almirall, S.A. · Sites in Austria
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 3 · Phase 4 3
First in 2010; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 378 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 36 across the 14 interventional studies, 201 across the 6 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Polichem S.A., one of the names counted as Almirall, S.A.. Under that name alone:
Polichem S.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Psoriasis by Almirall, S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to confirm the clinical efficacy and the safety of P-3073 in patients affected by isolated psoriatic nail(s) and/or those with psoriatic nails and concomitant mild to moderate plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
P-3073
Drug: P-3073
vehicle of P-3073
Drug: Vehicle of P-3073
Change in total Nail Psoriasis Severity Index (NAPSI)
Time frame: Baseline - Week 24
Change in NAPSI matrix
Time frame: Baseline - Week 24
Change in NAPSI bed
Time frame: Week 24
Nail Physician Global Assessment (PGA) response rate
Time frame: Week 24
Change in patient's quality-of-life by means of the Dermatology Life Quality Index (DLQI)
Time frame: Baseline - Week 24
Change in discomfort by means of the Visual Analogue Scale (VAS)
Time frame: Week 24
Proportions of nails with improvement in total NAPSI
Time frame: Week 24
Proportions of nails with improvement in NAPSI Matrix
Time frame: Week 24
Proportions of nails with improvement in NAPSI bed
Time frame: Week 24
Overall safety by recording any AE during the entire study duration and the local tolerability by means of severity scores for skin irritation.
Time frame: Week 24
Ran from Nov 2015 to primary completion in Feb 2017, 14 months.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.